Here we aimed to examine how blood and CSF NfL concentrations reflect disease severity and progression in MSA by combining clinical scores, regional brain atrophy rate and NfL levels in a large, multicentre, longitudinal cohort to help inform the design, patient stratification at baseline and monitor treatment response in future MSA clinical trials. Here, NEFL is linked to Brain atrophy.